Blurbs

Robert W. Baird Reiterates Their Buy Rating on AdaptHealth (AHCO)

In a report issued on February 24, Eric Coldwell from Robert W. Baird reiterated a Buy rating on AdaptHealth (AHCOResearch Report), with a price target of $26.00. The company’s shares closed last Friday at $16.20, close to its 52-week low of $13.95.

According to TipRanks.com, Coldwell is a 5-star analyst with an average return of 11.3% and a 57.3% success rate. Coldwell covers the Healthcare sector, focusing on stocks such as Quest Diagnostics, AmerisourceBergen, and Cardinal Health.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for AdaptHealth with a $29.00 average price target, which is a 92.6% upside from current levels. In a report issued on February 18, Leerink Partners also maintained a Buy rating on the stock with a $32.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on AdaptHealth’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $653 million and net profit of $58.09 million. In comparison, last year the company earned revenue of $284 million and had a GAAP net loss of $51.04 million.

Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AHCO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AdaptHealth Corp. provides medical products for both rental and sale. It focuses on respiratory and/or mobility equipment, including CPAP sleep equipment, oxygen equipment, wheelchairs, walkers, and hospital beds. The company was founded in 2012 and is headquartered in Plymouth Meeting, PA.

Read More on AHCO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos